ReviewReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2013
Prognostic factors and survival in metastatic breast cancer: A single institution experience.
Review in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic literature review of prognostic factors in patients with HR+/HER2- advanced breast cancer in Japan.Japanese journal of clinical oncology · 2021Pooled it
- Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre-Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.Cancer medicine · 2026Article
- Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.Breast cancer (Dove Medical Press) · 2026Article
- Liver transplantation for organ failure following multiple locoregional treatments for breast cancer metastasis.Annals of hepato-biliary-pancreatic surgery · 2024Article
- Clinicopathological features, treatment patterns, and survival outcomes among Syrian patients with advanced breast cancer.Frontiers in oncology · 2024Article
- Delayed diagnosis and increased mortality risk: Assessing the effects of the COVID-19 pandemic on breast cancer recurrence.Clinics (Sao Paulo, Brazil) · 2024Article
- The different clonal origins of metachronous and synchronous metastases.Journal of cancer research and clinical oncology · 2023Article
- Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer.The oncologist · 2023Article
- Metastatic breast cancer in Kenya: survival, prognosis and management at a tertiary referral centre.Ecancermedicalscience · 2023Article
- Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.Scientific reports · 2022Observational
- Article
- Prognostic factors for patients with metastatic breast cancer: a literature review.Translational cancer research · 2021Article
- Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model.Human vaccines & immunotherapeutics · 2021Article
- Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review.Cancer management and research · 2021Review
- Current practice patterns of osteoporosis treatment in cancer patients and effects of therapeutic interventions in a tertiary center.PloS one · 2021Article
- Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital.BMJ open · 2020Article
- A Prospective, Randomized, Placebo-Controlled Study of a Combination of Simvastatin and Chemotherapy in Metastatic Breast Cancer.Journal of oncology · 2020Article
- Article
- Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.Breast cancer research and treatment · 2018Article
- Effecst of Patho- Biological Factors on the Survival of Recurrent Breast Cancer CasesAsian Pacific journal of cancer prevention : APJCP · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current retrospective study aims to identify some determinants of survival in metastatic breast cancer.
methodsThe study concerned 332 patients with synchronous (SM) or metachronous (MM) metastatic breast cancer treated between January 2000 and December 2007. Statistical comparison between subgroups of patients concerning survival was carried out employing log-rank test for the invariable analysis and Cox model for the multivariable analysis. Factors included: age group (≤50 years vs. >50; ≤70 years vs. >70; ≤35 years vs. >35), menopausal status, presentation of metastatic disease (SM vs. MM), disease free interval (DFI) (≤24 months vs. >24 months; ≤60 months vs. >60 months), performance status at diagnosis of metastatic disease (PS) (0-1 vs. >1), hormone receptors (HR), number of metastatic sites (1 site vs. >1), nature of the metastatic site (visceral vs. non visceral), first line therapy, surgery of the primary tumor (SPT), locoregional radiotherapy (LRRT) and use or not of bisphosphonates.
resultsOverall survival at 5 years was 12%. Positive prognostic factors in univariate analysis were: age ≤ 70 years, hormono-dependence of the tumor, good PS (PS 0-1), less than two metastatic sites, no visceral metastases, DFI ≥ 24 months, SPT or LRRT. In multivariate analysis, favorable independent prognostic factors included: good PS (PS 0-1), absence of visceral metastases (liver, lung, brain) and age ≤ 70 years.
conclusionMany of the prognostic factors in metastatic breast cancer found in our study are known in the literature but some of them, like the application of locoregional treatment (radiotherapy or surgery) and the use of bisphosphonates, need to be further investigated in randomized clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.